Rickettsia prowazekii is one of the most lethal bacterial pathogens known to man;it has decimated entire armies and has been weaponized. It is a category B biothreat select agent because of transmissibility by aerosol, low infectious dose, high stability, and causation of severe illness with a high case-fatality ratio. The development of a cross-reactive vaccine is feasible because natural rickettsial infection provides protective immunity in survivors of epidemic (as well as murine) typhus, and because cross-protection has been demonstrated experimentally;nevertheless, safe and effective vaccines do not exist because of our incomplete understanding of the immune correlates of protection, and because the protective antigens remain unidentified. Thus, the objective of this application is to discover cross-protective rickettsial antigens recognized by T and B lymphocytes. We hypothesize that a subunit vaccine based on cross-reactive rickettsial antigens will protect mice, and a novel humanized mouse model, from lethal homologous and heterologous rickettsial challenges. This investigation will contribute to the long-term goal of developing immunotherapeutic agents for humans against rickettsiae.
Five specific aims with genome-wide approaches will address the hypothesis: 1) identify immunological correlates of protection against rickettsial infection;2) identify new MHC class l-restricted cross-reactive rickettsial antigens recognized by CD8+ T lymphocytes;3) identify MHC class ll-restricted cross-reactive rickettsial antigens recognized by CD4+ T lymphocytes;4) identify cross-reactive rickettsial antigens recognized by anti-rickettsial antibodies;and 5) determine the protection conferred by a subunit vaccine against a lethal challenge with Rickettsia.
The first aim will provide critical definitions of immune correlates of protection that will guide the selection and evaluation of vaccination protocols.
Aims 2, 3, and 4 will identify rickettsial T cell and B cell antigens through a systematic evaluation of all R. prowazekii genes. The fifth aim will identify a vaccine formulation and vaccination protocol that will provide a durable multifunctional and cross-reactive protective immune response. In this way, our research directly addresses WRCE's strategic plan and NIAID's Biodefense Research Agenda. The innovation of this research lies in the systematic definition of immune correlates of protection, the discovery of rickettsial antigens through a comprehensive genomic screen, the testing of multiple vaccine formulations, and the use of a highly relevant mouse model with a reconstituted functional human immune system.

Public Health Relevance

We will develop an anti-R/c/cetts/a subunit vaccine that will be an efficient deterrent to the weaponization of R. prowazekii. This vaccine will be an important resource to prevent an underestimated number of deaths and the severe morbidity caused by R. prowazekii and R. typhi throughout the world.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057156-10
Application #
8440804
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2015-02-28
Support Year
10
Fiscal Year
2013
Total Cost
$238,055
Indirect Cost
$35,183
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Navarro, Juan-Carlos; Giambalvo, Dileyvic; Hernandez, Rosa et al. (2016) Isolation of Madre de Dios Virus (Orthobunyavirus; Bunyaviridae), an Oropouche Virus Species Reassortant, from a Monkey in Venezuela. Am J Trop Med Hyg 95:328-38
Park, Arnold; Yun, Tatyana; Hill, Terence E et al. (2016) Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality. J Gen Virol 97:839-43
Aghazadeh, Amirali; Lin, Adam Y; Sheikh, Mona A et al. (2016) Universal microbial diagnostics using random DNA probes. Sci Adv 2:e1600025
Inglis, Fiona M; Lee, Kim M; Chiu, Kevin B et al. (2016) Neuropathogenesis of Chikungunya infection: astrogliosis and innate immune activation. J Neurovirol 22:140-8
Hatcher, Christopher L; Mott, Tiffany M; Muruato, Laura A et al. (2016) Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders. Infect Immun 84:2345-54
Chen, Hui; Hagström, Anna E V; Kim, Jinsu et al. (2016) Flotation Immunoassay: Masking the Signal from Free Reporters in Sandwich Immunoassays. Sci Rep 6:24297
Crannell, Zachary Austin; Cabada, Miguel Mauricio; Castellanos-Gonzalez, Alejandro et al. (2015) Recombinase polymerase amplification-based assay to diagnose Giardia in stool samples. Am J Trop Med Hyg 92:583-7
Walker, David H; Dumler, J Stephen (2015) The role of CD8 T lymphocytes in rickettsial infections. Semin Immunopathol 37:289-99
Mott, Tiffany M; Vijayakumar, Sudhamathi; Sbrana, Elena et al. (2015) Characterization of the Burkholderia mallei tonB Mutant and Its Potential as a Backbone Strain for Vaccine Development. PLoS Negl Trop Dis 9:e0003863
Gregory, Anthony E; Judy, Barbara M; Qazi, Omar et al. (2015) A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine 11:447-56

Showing the most recent 10 out of 362 publications